NVAX - 1.48 Pre-market now at 1.54/1.55 Genocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes http://stockcharts.com/c-sc/sc?s=NVAX&p=D&b=5&g=0&i=t82260490691&r=1500898138296 http://stockcharts.com/c-sc/sc?s=NVAX&p=W&b=5&g=0&i=t96569432202&r=1500898158783